Supplementary Table 8. Categorization of salvage regimens from overall 36 randomized controlled trials with 77 intervention arms

Category	Previous failed regimen		Interventions (number of intervention arms)
2nd line, 23 studies, 47 arms	PAC fail, 15 studies, 31 arms	Bismuth quadruple (n = 12)	PBTM (n = 9)[a]
			PBTA (n = 2)
			PBMA (n = 2)
		Quinolone triple (n = 9)	PAL (n = 8)[a]
			PML (n = 1)
		Quinolone quadruple (n = 5)	Levo-bismuth + AMX (PBLA) (n = 2)
			Levo-bismuth + tetra (PBLT) (n = 1)
			Levo-sequential (PA-PML) (n = 2)
		Others (n = 4)	PAM (n = 2)
			PAT (n = 1)
			PATM (n = 1)
			Concomitant (PACM) (n = 1)
	PAM fail, 1 study, 2 arms		PB + furazolidone + levofloxacin (n = 1)
			PB + furazolidone + rlufoxacin (n = 1)
	PAC/M fail, 2 studies, 4 arms		Levo-bismuth (PBLA) (n = 1)
			PBTM (n = 1)
			Furazolidone + PL (n = 1)
			Furazolidone + PB + doxycycline (n = 1)
	Triple, n-s, 2 studies, 4 arms		Sequential (PA-PC + tinidazole) (n = 1)
			PBTM (tetracycline/doxycyline) (n = 1)
			PBTM (n = 1)
			PM + moxifloxacin (n = 1)
	PBAC/M, 2 studies, 4 arms		Quintuple: PBTM + oxfloxacin (n = 1)
			Quintuple: PBAC + tinidazole (n = 1)
			PBAC (n = 1)
			PB + ofloxacin + azithromycin (n = 1)
	N-S, 2 studies, 5 arms		PAL (n = 2)
			Levo-sequential (PA-PML) (n = 1)
			High dose dual (PA) (n = 1)
			Sequential (PA-PCM) (n = 1)
3rd line, 5 studies, 11 arms	PAC-PAM fail, 3 studies, 7 arms	Quinolone triple (n = 5)	PA + sitafloxacin (n = 2)
			PM + sitafloxacin (n = 1)
			PAL (n = 1)
			PA + gatifloxacin (n = 1)
		Dual (not high dose) (n = 2)	PA (n = 2)
	PACM + Quinolone fail, 2 studies, 4 arms		PBTM (n = 1)
			PBMA (n = 1)
			PB + minocycline + tinidazole (n = 1)
			PB + minocycline + rifabutin (n = 1)

Supplementary Table 8. Continued

Category	Previous failed regimen	Interventions (number of intervention arms)
Duration, 5 studies, 12 arms	PAC fail, 3 studies	PBTM, 7d vs. 14d, 3 studies[a]
	PAC/M fail, 1 study	PAL, 7d vs. 10d, 1 study (levofloxacin 500 mg vs. 1,000 mg)
	PAC-PAM (-Sitafloxacin regimen) fail, 1 study	PA+rifabutin, 10d vs. 14d, 1 study
PPI comparison, 2 studies, 4 arms	PAC-PBTM fail, 1 study	Rifabutin+amoxicillin 1g tid + PPI standard vs. double dose bid, 1 study
	PAC fail, 1 study	PBTM: rabeprazole vs. esomeprazole, 1 study

P, proton pump inhibitor; A, amoxicillin; C, clarithromycin; B, bismuth; T, tetracycline; M, metronidazole; L, levofloxacin; n-s, not significant; PPI, proton pump inhibitor.

[a]Included in the meta-analysis.